Cipla USA Inc., a subsidiary of the renowned global pharmaceutical company Cipla Limited, is headquartered in the United States and operates extensively across North America. Founded in 1935, Cipla has established itself as a leader in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of a diverse range of high-quality generic and branded medications. Cipla USA is particularly noted for its commitment to providing affordable healthcare solutions, specialising in areas such as respiratory, oncology, and anti-infective therapies. The company’s innovative approach to drug formulation and delivery sets it apart in a competitive market. With a strong emphasis on research and development, Cipla USA has achieved significant milestones, including numerous FDA approvals, solidifying its position as a trusted provider of essential medicines.
How does Cipla USA Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cipla USA Inc.'s score of 47 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cipla USA Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Cipla Limited, which may influence its climate commitments and performance metrics. Cipla USA Inc. inherits its climate-related data from its parent company, Cipla Limited, at a cascade level of 1. However, no specific reduction targets or initiatives have been documented for Cipla USA Inc. itself. The absence of documented reduction targets suggests that the company may be aligning its climate strategy with broader corporate initiatives set by Cipla Limited. As part of its corporate family, Cipla USA Inc. may benefit from the sustainability practices and commitments of Cipla Limited, which is actively engaged in addressing climate change. Nonetheless, without specific emissions data or reduction targets, it is challenging to assess Cipla USA Inc.'s individual impact or commitments in the context of carbon emissions and climate action.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 48,146,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 236,358,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Cipla USA Inc.'s Scope 3 emissions, which increased by 10% last year and increased by approximately 10% since 2024, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 53% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cipla USA Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.